Do alterations in prostanoid or catecholamine release influence the antiarrhythmic activity of nicergoline?

F. M. Williams, S. J. Coker, H. G. Dean, K. A. Kane, J. R. Parratt

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We examined the effects of nicergoline, an α-adrenoceptor blocking drug and an inhibitor of platelet phospholipase, on haemodynamics, blood gases, cardiac arrhythmias, and prostanoid and catecholamine release in anaesthetised greyhounds before, during, and after a 40-min occlusion of the left anterior descending coronary artery. Twenty-five minutes after commencing the intravenous infusion of nicergoline (50 μg kg-1) there were significant reductions in heart rate, arterial blood pressure, left ventricular dP/dtmax, and cardiac output. Nicergoline also increased the O2 extraction by the myocardium both before and during coronary artery occlusion. In contrast to control animals, heart rate decreased but there were no further reductions in arterial blood pressure during the occlusion period. Nicergoline improved survival (from 17 in control dogs to 50%) following the combined period of myocardial ischaemia and reperfusion and appeared to suppress the phase 1b occlusion-induced arrhythmias. The release of thromboxane B2 from the ischaemic myocardium was partially suppressed by nicergoline, and the ratio of 6-keto PGF/thromboxane B2 (the stable breakdown products of prostacyclin and thromboxane A2, respectively) was increased. The washout of noradrenaline and adrenaline from the ischaemic myocardium following release of the occlusion was slightly enhanced by nicergoline. It is concluded that the beneficial metabolic and prostacyclin-promoting properties of nicergoline may be opposed by its action on noradrenaline washout, thus limiting its antiarrhythmic effectiveness.

Original languageEnglish
Pages (from-to)286-293
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume8
Issue number2
Publication statusPublished - 1986

Fingerprint

Nicergoline
Prostaglandins
Catecholamines
Myocardium
Thromboxane B2
Epoprostenol
Cardiac Arrhythmias
Coronary Vessels
Norepinephrine
Arterial Pressure
Heart Rate
Myocardial Reperfusion
Thromboxane A2
Phospholipases
Coronary Occlusion
Platelet Aggregation Inhibitors
Intravenous Infusions
Cardiac Output
Adrenergic Receptors
Epinephrine

Keywords

  • Arrhythmias
  • Catecholamines
  • Coronary artery occlusion
  • Nicergoline
  • Prostanoids
  • Reperfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Do alterations in prostanoid or catecholamine release influence the antiarrhythmic activity of nicergoline? / Williams, F. M.; Coker, S. J.; Dean, H. G.; Kane, K. A.; Parratt, J. R.

In: Journal of Cardiovascular Pharmacology, Vol. 8, No. 2, 1986, p. 286-293.

Research output: Contribution to journalArticle

@article{2e9e3900f0f34c42b428443ed44f7d78,
title = "Do alterations in prostanoid or catecholamine release influence the antiarrhythmic activity of nicergoline?",
abstract = "We examined the effects of nicergoline, an α-adrenoceptor blocking drug and an inhibitor of platelet phospholipase, on haemodynamics, blood gases, cardiac arrhythmias, and prostanoid and catecholamine release in anaesthetised greyhounds before, during, and after a 40-min occlusion of the left anterior descending coronary artery. Twenty-five minutes after commencing the intravenous infusion of nicergoline (50 μg kg-1) there were significant reductions in heart rate, arterial blood pressure, left ventricular dP/dtmax, and cardiac output. Nicergoline also increased the O2 extraction by the myocardium both before and during coronary artery occlusion. In contrast to control animals, heart rate decreased but there were no further reductions in arterial blood pressure during the occlusion period. Nicergoline improved survival (from 17 in control dogs to 50{\%}) following the combined period of myocardial ischaemia and reperfusion and appeared to suppress the phase 1b occlusion-induced arrhythmias. The release of thromboxane B2 from the ischaemic myocardium was partially suppressed by nicergoline, and the ratio of 6-keto PGF1α/thromboxane B2 (the stable breakdown products of prostacyclin and thromboxane A2, respectively) was increased. The washout of noradrenaline and adrenaline from the ischaemic myocardium following release of the occlusion was slightly enhanced by nicergoline. It is concluded that the beneficial metabolic and prostacyclin-promoting properties of nicergoline may be opposed by its action on noradrenaline washout, thus limiting its antiarrhythmic effectiveness.",
keywords = "Arrhythmias, Catecholamines, Coronary artery occlusion, Nicergoline, Prostanoids, Reperfusion",
author = "Williams, {F. M.} and Coker, {S. J.} and Dean, {H. G.} and Kane, {K. A.} and Parratt, {J. R.}",
year = "1986",
language = "English",
volume = "8",
pages = "286--293",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Do alterations in prostanoid or catecholamine release influence the antiarrhythmic activity of nicergoline?

AU - Williams, F. M.

AU - Coker, S. J.

AU - Dean, H. G.

AU - Kane, K. A.

AU - Parratt, J. R.

PY - 1986

Y1 - 1986

N2 - We examined the effects of nicergoline, an α-adrenoceptor blocking drug and an inhibitor of platelet phospholipase, on haemodynamics, blood gases, cardiac arrhythmias, and prostanoid and catecholamine release in anaesthetised greyhounds before, during, and after a 40-min occlusion of the left anterior descending coronary artery. Twenty-five minutes after commencing the intravenous infusion of nicergoline (50 μg kg-1) there were significant reductions in heart rate, arterial blood pressure, left ventricular dP/dtmax, and cardiac output. Nicergoline also increased the O2 extraction by the myocardium both before and during coronary artery occlusion. In contrast to control animals, heart rate decreased but there were no further reductions in arterial blood pressure during the occlusion period. Nicergoline improved survival (from 17 in control dogs to 50%) following the combined period of myocardial ischaemia and reperfusion and appeared to suppress the phase 1b occlusion-induced arrhythmias. The release of thromboxane B2 from the ischaemic myocardium was partially suppressed by nicergoline, and the ratio of 6-keto PGF1α/thromboxane B2 (the stable breakdown products of prostacyclin and thromboxane A2, respectively) was increased. The washout of noradrenaline and adrenaline from the ischaemic myocardium following release of the occlusion was slightly enhanced by nicergoline. It is concluded that the beneficial metabolic and prostacyclin-promoting properties of nicergoline may be opposed by its action on noradrenaline washout, thus limiting its antiarrhythmic effectiveness.

AB - We examined the effects of nicergoline, an α-adrenoceptor blocking drug and an inhibitor of platelet phospholipase, on haemodynamics, blood gases, cardiac arrhythmias, and prostanoid and catecholamine release in anaesthetised greyhounds before, during, and after a 40-min occlusion of the left anterior descending coronary artery. Twenty-five minutes after commencing the intravenous infusion of nicergoline (50 μg kg-1) there were significant reductions in heart rate, arterial blood pressure, left ventricular dP/dtmax, and cardiac output. Nicergoline also increased the O2 extraction by the myocardium both before and during coronary artery occlusion. In contrast to control animals, heart rate decreased but there were no further reductions in arterial blood pressure during the occlusion period. Nicergoline improved survival (from 17 in control dogs to 50%) following the combined period of myocardial ischaemia and reperfusion and appeared to suppress the phase 1b occlusion-induced arrhythmias. The release of thromboxane B2 from the ischaemic myocardium was partially suppressed by nicergoline, and the ratio of 6-keto PGF1α/thromboxane B2 (the stable breakdown products of prostacyclin and thromboxane A2, respectively) was increased. The washout of noradrenaline and adrenaline from the ischaemic myocardium following release of the occlusion was slightly enhanced by nicergoline. It is concluded that the beneficial metabolic and prostacyclin-promoting properties of nicergoline may be opposed by its action on noradrenaline washout, thus limiting its antiarrhythmic effectiveness.

KW - Arrhythmias

KW - Catecholamines

KW - Coronary artery occlusion

KW - Nicergoline

KW - Prostanoids

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=0022574627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022574627&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 286

EP - 293

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -